STOCK TITAN

Veracyte - VCYT STOCK NEWS

Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.

Veracyte, Inc. (symbol: VCYT) is a pioneering genomic diagnostics company dedicated to significantly enhancing patient care through innovative diagnostic solutions. The company specializes in developing and providing genomic diagnostic products and services that improve clinical outcomes by resolving the uncertainties inherent in traditional diagnostic methods.

Veracyte's core business revolves around creating tests that offer more accurate diagnoses without resorting to risky, costly, and often unnecessary surgeries. By employing top-tier scientific rigor, state-of-the-art tools, and the brightest minds in the field, Veracyte delivers diagnostic solutions that bring clarity and assurance to patients and physicians alike.

The company's product portfolio includes the Afirma analysis, Percepta, Envisia, and other cutting-edge diagnostic tests. These products are designed to tackle diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. Veracyte's diagnostic tests are distinguished by their ability to provide conclusive results where traditional methods fall short, thereby sparing patients from unnecessary surgical procedures.

Recent achievements highlight Veracyte's commitment to innovation and excellence. The company consistently introduces evidence that sets new standards in genomic tests, fundamentally altering current clinical practice norms. This commitment to scientific excellence ensures that Veracyte remains at the forefront of the genomic diagnostics industry.

Veracyte's impact extends beyond just clinical outcomes; it significantly influences the lives of both patients and physicians by offering a clearer path forward. Through continuous research, strategic partnerships, and an unwavering dedication to improving patient care, Veracyte stands out as a leader in the genomic diagnostics field.

Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) will be presenting at the 42nd annual J.P. Morgan Healthcare Conference on January 8, 2024, at 1:30 p.m. Pacific Time. The CEO and CFO will be presenting, and a live webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.51%
Tags
conferences
-
Rhea-AI Summary
Veracyte, Inc. (VCYT) announced new data presented at the 24th Annual Meeting of the Society of Urologic Oncology, highlighting clinical observations and translational research on the Decipher Prostate Genomic Classifier. The studies support its clinical utility in the treatment and management of prostate cancer, particularly for active surveillance candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
none
-
Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) has announced that its Percepta Nasal Swab test has been found to accurately determine lung cancer risk among current and former smokers with lung nodules, potentially avoiding unnecessary invasive procedures and accelerating appropriate treatment. The test is simple, non-invasive, and provides insights to objectively assess lung cancer risk, guiding physicians in determining which patients to work up for lung cancer and which to monitor with imaging.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
none
Rhea-AI Summary
Veracyte, Inc. (VCYT) will present seven posters at the 24th Annual Meeting of the Society of Urologic Oncology, showcasing the clinical performance of its Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment. The posters will report data from over 60,000 patients, addressing the ongoing challenge in prostate cancer management. The company aims to provide a more complete understanding of each patient's cancer for personalized care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
none
-
Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) Grew Total Revenue to $90.1 million, an Increase of 19%
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.58%
Tags
-
Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) announces multi-year agreement with Illumina, Inc. (Nasdaq: ILMN) to develop high-performing molecular tests for decentralized in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx NGS instrument, part of Veracyte’s expanded IVD approach. The first tests to be developed are Prosigna Breast Cancer Assay and Percepta Nasal Swab test, aimed at improving diagnostic and treatment decisions for breast cancer and lung nodules. Illumina's NextSeq 550Dx instrument offers validated mid-throughput platform with regulatory approvals in over 60 countries, broadening market access and enabling faster turnaround times for patients and physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.58%
Tags
none
Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) announced that CFO Rebecca Chambers will participate in a fireside chat at the Stephens Annual Investment Conference on November 15 at 3:00 p.m. ET. A live webcast will be available on Veracyte's website, with a replay available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.13%
Tags
conferences
-
Rhea-AI Summary
Veracyte, Inc. announces two poster presentations at SITC 2023 showcasing the potential of their tools in immuno-oncology drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
none
-
Rhea-AI Summary
Veracyte, Inc. to release financial results for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
Rhea-AI Summary
Veracyte, Inc. presents new data demonstrating the clinical utility of the Envisia Genomic Classifier for diagnosing interstitial lung diseases (ILDs). The studies show that adding the Envisia Genomic Classifier to the diagnostic process improves the ability to detect usual interstitial pneumonia (UIP), a hallmark of idiopathic pulmonary fibrosis and ILDs that are more likely to progress over time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.82%
Tags
none

FAQ

What is the current stock price of Veracyte (VCYT)?

The current stock price of Veracyte (VCYT) is $39.18 as of February 21, 2025.

What is the market cap of Veracyte (VCYT)?

The market cap of Veracyte (VCYT) is approximately 3.3B.

What does Veracyte, Inc. specialize in?

Veracyte, Inc. specializes in genomic diagnostics to improve patient care by resolving inconclusive results from traditional diagnostic methods.

What products does Veracyte offer?

Veracyte offers genomic diagnostic products such as Afirma, Percepta, and Envisia, targeting diseases like thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis.

How do Veracyte's tests improve clinical outcomes?

Veracyte's tests provide accurate diagnoses, reducing the need for risky and unnecessary surgeries by resolving ambiguity in traditional diagnostic methods.

What recent achievements has Veracyte accomplished?

Veracyte has consistently introduced evidence that sets new standards in genomic tests, changing today's clinical practice standards.

Who benefits from Veracyte's genomic diagnostic solutions?

Both patients and physicians benefit as Veracyte's tests offer clearer diagnostic paths, improving overall patient care and reducing unnecessary medical procedures.

In which diseases does Veracyte focus its diagnostic solutions?

Veracyte focuses on diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis.

What sets Veracyte apart from traditional diagnostic companies?

Veracyte leverages top-tier scientific rigor, advanced tools, and unmatched expertise to deliver unprecedented diagnostic accuracy without unnecessary surgeries.

How does Veracyte impact clinical practice standards?

Veracyte's innovative genomic tests provide evidence that fundamentally alters clinical practice standards, ensuring more accurate and less invasive diagnosis methods.

What is the significance of Veracyte's Afirma analysis?

The Afirma analysis is a key product in Veracyte's portfolio, offering accurate diagnosis for conditions like thyroid cancer, thus avoiding unnecessary surgeries.

Why is Veracyte considered a leader in genomic diagnostics?

Veracyte leads the industry due to its innovative solutions, consistent introduction of new evidence, and significant impact on improving patient care and clinical practices.
Veracyte

Nasdaq:VCYT

VCYT Rankings

VCYT Stock Data

3.29B
76.83M
0.78%
104.5%
3.93%
Diagnostics & Research
Services-medical Laboratories
Link
United States
SOUTH SAN FRANCISCO